CompletedNCT01710709
Aripiprazole Long-Acting Injections for Bipolarity Maintenance
About this title
Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder
Read the official source — NCT01710709This study evaluated the effectiveness of Aripiprazole for people with bipolarity.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the effectiveness of Aripiprazole for people with bipolarity.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
What did participation involve?
The study group receives aripiprazole as a study medication.
- Listed locations
- Birmingham and 141 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 748
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Canada, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01710709
- Official title
Show the full official title
A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedBirmingham, United States · Little Rock, United States · Rogers, United States
107 more locations
- Bellflower, United States
- Beverly Hills, United States
- Costa Mesa, United States
- Culver City, United States
- Garden Grove, United States
- Lemon Grove, United States
- Oakland, United States
- Orange, United States
- Pico Rivera, United States
- Riverside, United States
- San Diego, United States
- Temecula, United States
- Upland, United States
- Wildomar, United States
- Colorado Springs, United States
- Gainesville, United States
- Hialeah, United States
- Jacksonville, United States
- Leesburg, United States
- Orlando, United States
- Tampa, United States
- Atlanta, United States
- Decatur, United States
- Smyrna, United States
- Chicago, United States
- Hinsdale, United States
- Naperville, United States
- Schaumburg, United States
- Prairie Village, United States
- Lake Charles, United States
- Baltimore, United States
- Gaithersburg, United States
- Boston, United States
- O'Fallon, United States
- St Louis, United States
- Lincoln, United States
- Berlin, United States
- Cherry Hill, United States
- Brooklyn, United States
- Buffalo, United States
- New York, United States
- Rochester, United States
- Staten Island, United States
- Cincinnati, United States
- Oklahoma City, United States
- Portland, United States
- Allentown, United States
- Media, United States
- Columbia, United States
- Memphis, United States
- Arlington, United States
- Austin, United States
- Dallas, United States
- Plano, United States
- Sugar Land, United States
- Wichita Falls, United States
- Orem, United States
- Salt Lake City, United States
- Richmond, United States
- Bellevue, United States
- Spokane, United States
- Middleton, United States
- Kentville, Canada
- Chatham, Canada
- Élancourt, France
- Limoges, France
- Nîmes, France
- Toulouse, France
- Budapest, Hungary
- Nyireghaza, Hungary
- Vác, Hungary
- Fukuoka, Japan
- Fukushima, Japan
- Gunma, Japan
- Ibaraki, Japan
- Iizuka, Japan
- Kanagawa, Japan
- Kochi, Japan
- Kouchi, Japan
- Kumamoto, Japan
- Nagano-ken, Japan
- Okayama, Japan
- Okinawa, Japan
- Osaka, Japan
- Sapporo, Japan
- Shizuoka, Japan
- Tokyo, Japan
- Yamagata, Japan
- Yatsushiro, Japan
- Johor Bahru, Malaysia
- Perak, Malaysia
- Sarawak, Malaysia
- Bydgoszcz, Poland
- Chełmno, Poland
- Choroszcz, Poland
- Gdansk, Poland
- Lublin, Poland
- Pruszków, Poland
- Tuszyn, Poland
- Bucharest, Romania
- Iași, Romania
- Targoviste, Romania
- Târgu Mureş, Romania
- Goyang-si, South Korea
- Jeju City, South Korea
- Seoul, South Korea
- Taipei, Taiwan
Questions about this study
What did researchers investigate?
This study evaluated the effectiveness of Aripiprazole for people with bipolarity.
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
